Potluri VS, Goldberg DS, Mohan S, et al. - In order to clarify whether donor HCV-viremia or recipient HCV-serostatus can influence allograft function among HCV-seronegative recipients of HCV-viremic kidneys, researchers analyzed trends in HCV-viremic kidney use between 4/1/2015 and 3/31/2019, using national United States registry data. They also compared eGFR for similar kidneys transplanted into highly similar recipients of kidney transplants, using advanced matching methods. The receipt of the majority of kidneys transplanted from HCV-viremic donors by HCV-seronegative patients was reported, by 2019. Based on 1-year allograft function, the underestimation of the quality of HCV-viremic kidneys by widely used organ quality scores was reported. Findings revealed no link of recipient HCV-serostatus with worse short-term allograft function using HCV-viremic kidneys.